Tags

Type your tag names separated by a space and hit enter

Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort.
Eur J Cancer Prev 2010; 19(2):120-5EJ

Abstract

Metabolic syndrome, including low HDL cholesterol, has been associated with an increased breast cancer risk, whereas little is known of the relationship with total cholesterol. Cox proportional hazards regression models were performed to evaluate the association between self-reported total serum cholesterol, cholesterol-lowering drugs, and risk of breast cancer in 69 088 women from the French E3N cohort study. A total of 2932 cases of primary invasive breast cancer were reported during 12 years of follow-up. Compared with women with low/normal serum cholesterol (<6.6 mol/l), users of cholesterol-lowering drugs had a significantly decreased breast cancer risk [hazard ratio (HR): 0.79, 95% confidence interval (CI): 0.68, 0.93]. There was no variation in HRs according to the menopausal status. In strata defined by the hormone receptor status of the tumor, the risk reached statistical significance only for the estrogen-positive and progesterone-positive receptor subtype (HR: 0.64, 95% CI: 0.50, 0.82). A high cholesterol without cholesterol-lowering drug use was not associated with breast cancer risk (HR: 0.99, 95% CI: 0.85, 1.15) in the entire population. Our result concerning cholesterol-lowering drugs is consistent with studies showing that hypolipidemic molecules are effective in inhibiting cancer cell growth proliferation. Further studies should investigate whether these findings apply to all classes of cholesterol-lowering drugs.

Authors+Show Affiliations

Institut National de la Santé et de la Recherche Médicale, ERI-20, EA4045 Paris-Sud Université, and Institut Gustave Roussy, Villejuif, France.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20042864

Citation

Fagherazzi, Guy, et al. "Serum Cholesterol Level, Use of a Cholesterol-lowering Drug, and Breast Cancer: Results From the Prospective E3N Cohort." European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), vol. 19, no. 2, 2010, pp. 120-5.
Fagherazzi G, Fabre A, Boutron-Ruault MC, et al. Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev. 2010;19(2):120-5.
Fagherazzi, G., Fabre, A., Boutron-Ruault, M. C., & Clavel-Chapelon, F. (2010). Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), 19(2), pp. 120-5. doi:10.1097/CEJ.0b013e3283354918.
Fagherazzi G, et al. Serum Cholesterol Level, Use of a Cholesterol-lowering Drug, and Breast Cancer: Results From the Prospective E3N Cohort. Eur J Cancer Prev. 2010;19(2):120-5. PubMed PMID: 20042864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. AU - Fagherazzi,Guy, AU - Fabre,Alban, AU - Boutron-Ruault,Marie-Christine, AU - Clavel-Chapelon,Françoise, PY - 2010/1/1/entrez PY - 2010/1/1/pubmed PY - 2010/4/14/medline SP - 120 EP - 5 JF - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JO - Eur. J. Cancer Prev. VL - 19 IS - 2 N2 - Metabolic syndrome, including low HDL cholesterol, has been associated with an increased breast cancer risk, whereas little is known of the relationship with total cholesterol. Cox proportional hazards regression models were performed to evaluate the association between self-reported total serum cholesterol, cholesterol-lowering drugs, and risk of breast cancer in 69 088 women from the French E3N cohort study. A total of 2932 cases of primary invasive breast cancer were reported during 12 years of follow-up. Compared with women with low/normal serum cholesterol (<6.6 mol/l), users of cholesterol-lowering drugs had a significantly decreased breast cancer risk [hazard ratio (HR): 0.79, 95% confidence interval (CI): 0.68, 0.93]. There was no variation in HRs according to the menopausal status. In strata defined by the hormone receptor status of the tumor, the risk reached statistical significance only for the estrogen-positive and progesterone-positive receptor subtype (HR: 0.64, 95% CI: 0.50, 0.82). A high cholesterol without cholesterol-lowering drug use was not associated with breast cancer risk (HR: 0.99, 95% CI: 0.85, 1.15) in the entire population. Our result concerning cholesterol-lowering drugs is consistent with studies showing that hypolipidemic molecules are effective in inhibiting cancer cell growth proliferation. Further studies should investigate whether these findings apply to all classes of cholesterol-lowering drugs. SN - 1473-5709 UR - https://www.unboundmedicine.com/medline/citation/20042864/Serum_cholesterol_level_use_of_a_cholesterol_lowering_drug_and_breast_cancer:_results_from_the_prospective_E3N_cohort_ L2 - http://dx.doi.org/10.1097/CEJ.0b013e3283354918 DB - PRIME DP - Unbound Medicine ER -